Business Description
SAB Biotherapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US78397T2024
Description
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.72 | |||||
| Equity-to-Asset | 0.69 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year FCF Growth Rate | -94.1 | |||||
| 3-Year Book Growth Rate | -11.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.67 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.03 | |||||
| 9-Day RSI | 36.96 | |||||
| 14-Day RSI | 42.78 | |||||
| 6-1 Month Momentum % | 46.97 | |||||
| 12-1 Month Momentum % | -58.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.69 | |||||
| Quick Ratio | 3.69 | |||||
| Cash Ratio | 3.45 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -28.5 | |||||
| Shareholder Yield % | -0.26 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -109.33 | |||||
| ROA % | -76.11 | |||||
| ROIC % | -196.46 | |||||
| ROC (Joel Greenblatt) % | -197.24 | |||||
| ROCE % | -88.83 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.7 | |||||
| Price-to-Tangible-Book | 0.7 | |||||
| EV-to-EBIT | -0.02 | |||||
| EV-to-EBITDA | -0.03 | |||||
| EV-to-Forward-Revenue | 54.53 | |||||
| EV-to-FCF | -0.03 | |||||
| Price-to-Net-Current-Asset-Value | 1.66 | |||||
| Price-to-Net-Cash | 1.92 | |||||
| Earnings Yield (Greenblatt) % | -5000 | |||||
| FCF Yield % | -148.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SABS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SAB Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.3 | ||
| Beta | 0.87 | ||
| Volatility % | 61.75 | ||
| 14-Day RSI | 42.78 | ||
| 14-Day ATR ($) | 0.325295 | ||
| 20-Day SMA ($) | 3.2985 | ||
| 12-1 Month Momentum % | -58.72 | ||
| 52-Week Range ($) | 2.16 - 9.677 | ||
| Shares Outstanding (Mil) | 9.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SAB Biotherapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SAB Biotherapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
SAB Biotherapeutics Inc Frequently Asked Questions
What is SAB Biotherapeutics Inc(SABS)'s stock price today?
The current price of SABS is $2.81. The 52 week high of SABS is $9.68 and 52 week low is $2.16.
When is next earnings date of SAB Biotherapeutics Inc(SABS)?
The next earnings date of SAB Biotherapeutics Inc(SABS) is 2025-03-28 Est..
Does SAB Biotherapeutics Inc(SABS) pay dividends? If so, how much?
SAB Biotherapeutics Inc(SABS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers